Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP

LMR Partners LLP increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 145.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,479 shares of the company’s stock after purchasing an additional 48,920 shares during the period. LMR Partners LLP owned 0.12% of Replimune Group worth $904,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its position in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new position in Replimune Group in the 2nd quarter worth about $57,000. Arizona State Retirement System acquired a new stake in shares of Replimune Group in the second quarter valued at approximately $108,000. Quest Partners LLC raised its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Replimune Group during the first quarter valued at approximately $140,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on REPL. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Tuesday, November 12th. JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Trading Up 1.7 %

Shares of Replimune Group stock opened at $10.95 on Wednesday. The business has a fifty day simple moving average of $11.47 and a 200-day simple moving average of $9.62. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $12.97. The firm has a market cap of $749.20 million, a price-to-earnings ratio of -3.59 and a beta of 1.19. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. On average, equities analysts forecast that Replimune Group, Inc. will post -3.02 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.